Gliflozins position update in the treatment algorithms for patients with type 2 diabetes mellitus and chronic kidney disease: new pathogenetic mechanisms and data from subanalyses of the large randomised control trails
The series of the cardiovascular outcome trails have demonstrated the nephroprotective properties of the gliflozins. Canagliflozin in the CREDENCE, which was the first study with a primary focus on the evaluation of the nephroprotective properties of gliflozin, have demonstrated the possibility to s...
Saved in:
| Main Authors: | O. Y. Sukhareva, Z. T. Zuraeva, M. S. Shamhalova |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2022-02-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/12864 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pathogenetic aspects of the influence of gliflozins on erythropoiesis and iron metabolism in patients with chronic heart failure
by: R. A. Khachaturyan, et al.
Published: (2024-04-01) -
Effect of SGLT2 inhibitors on the course of chronic heart failure in patients with type 2 diabetes mellitus
by: A. N. Payudis, et al.
Published: (2022-10-01) -
Assessment of Gliflozins prescribing pattern in a United Arab Emirates tertiary-level care hospital
by: Wessa Shenouda, et al.
Published: (2025-04-01) -
Effect of Sodium-Glucose Cotransporter Type 2 Inhibitors on The Development and Course of Atrial Fibrillation
by: D. A. Ishmaev, et al.
Published: (2025-01-01) -
Canagliflozin: from glycemic control to improvement of cardiovascular and renal prognosis in patients with type 2 diabetes mellitus. Resolution of Advisory Board
by: M. V. Shestakova, et al.
Published: (2022-01-01)